BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Get Free Report) EVP George Eric Davis sold 1,850 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $85.01, for a total value of $157,268.50. Following the completion of the transaction, the executive vice president now owns 56,157 shares of the company's stock, valued at approximately $4,773,906.57. The sale was disclosed in a document filed with the SEC, which is available at this link.
George Eric Davis also recently made the following trade(s):
- On Thursday, March 28th, George Eric Davis sold 24,602 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $88.34, for a total value of $2,173,340.68.
BioMarin Pharmaceutical Stock Down 0.4 %
BMRN opened at $82.10 on Tuesday. BioMarin Pharmaceutical Inc. has a one year low of $76.02 and a one year high of $99.56. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.70 and a current ratio of 2.74. The stock's fifty day moving average is $86.73 and its 200-day moving average is $89.02. The company has a market capitalization of $15.59 billion, a PE ratio of 76.73, a P/E/G ratio of 1.30 and a beta of 0.34.
Elon’s New Device is About to Shock the World
From InvestorPlace | Ad
Using this device you see above…
Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in…
“The next step in human evolution.”
Click here to see the details because there’s a lot of money at stake.
BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last announced its earnings results on Thursday, February 22nd. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.44 by $0.05. The company had revenue of $646.21 million for the quarter, compared to analyst estimates of $639.53 million. BioMarin Pharmaceutical had a return on equity of 5.34% and a net margin of 8.31%. BioMarin Pharmaceutical's revenue for the quarter was up 20.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.11 earnings per share. On average, equities analysts predict that BioMarin Pharmaceutical Inc. will post 1.98 EPS for the current fiscal year.
Institutional Investors Weigh In On BioMarin Pharmaceutical
A number of institutional investors and hedge funds have recently modified their holdings of BMRN. Capital Research Global Investors raised its position in shares of BioMarin Pharmaceutical by 79.0% during the fourth quarter. Capital Research Global Investors now owns 10,774,641 shares of the biotechnology company's stock worth $1,038,907,000 after purchasing an additional 4,756,671 shares during the period. Norges Bank acquired a new stake in shares of BioMarin Pharmaceutical during the fourth quarter worth $324,098,000. Barclays PLC raised its position in shares of BioMarin Pharmaceutical by 31.6% during the third quarter. Barclays PLC now owns 5,573,157 shares of the biotechnology company's stock worth $493,111,000 after purchasing an additional 1,336,886 shares during the period. Toronto Dominion Bank raised its position in shares of BioMarin Pharmaceutical by 1,832.5% during the third quarter. Toronto Dominion Bank now owns 907,754 shares of the biotechnology company's stock worth $80,318,000 after purchasing an additional 860,782 shares during the period. Finally, Avoro Capital Advisors LLC grew its holdings in shares of BioMarin Pharmaceutical by 11.7% during the fourth quarter. Avoro Capital Advisors LLC now owns 4,300,000 shares of the biotechnology company's stock valued at $414,606,000 after buying an additional 450,000 shares in the last quarter. 98.71% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Several research analysts have recently commented on BMRN shares. Scotiabank lifted their target price on BioMarin Pharmaceutical from $83.00 to $85.00 and gave the stock a "sector perform" rating in a research report on Thursday, April 25th. Royal Bank of Canada restated a "sector perform" rating and set a $100.00 price objective on shares of BioMarin Pharmaceutical in a research report on Friday, February 23rd. Cantor Fitzgerald restated an "overweight" rating and set a $110.00 price objective on shares of BioMarin Pharmaceutical in a research report on Thursday, April 25th. Citigroup reduced their price objective on BioMarin Pharmaceutical from $94.00 to $91.00 and set a "neutral" rating for the company in a research report on Thursday, April 25th. Finally, Wells Fargo & Company boosted their price objective on BioMarin Pharmaceutical from $100.00 to $110.00 and gave the company an "overweight" rating in a research report on Thursday, April 25th. Seven analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $107.50.
Read Our Latest Research Report on BMRN
BioMarin Pharmaceutical Company Profile
(
Get Free Report)
BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
